Advertisement

Topics

Celgene and BeiGene enter multi-faceted $1bn+ immuno-oncology deal

15:40 EDT 6 Jul 2017 | Elsevier Business Intelligence

Celgene Corp. licensed exclusive rights to BeiGene (Beijing) Co. Ltd.’s PD-1 inhibitor BGBA317 as part of a deal that also ...

Original Article: Celgene and BeiGene enter multi-faceted $1bn+ immuno-oncology deal

NEXT ARTICLE

More From BioPortfolio on "Celgene and BeiGene enter multi-faceted $1bn+ immuno-oncology deal"

Quick Search
Advertisement